Lumos Pharma, Inc. (NASDAQ:LUMO) Sees Large Increase in Short Interest

Lumos Pharma, Inc. (NASDAQ:LUMOGet Rating) saw a large growth in short interest in July. As of July 15th, there was short interest totalling 307,100 shares, a growth of 1,706.5% from the June 30th total of 17,000 shares. Based on an average daily volume of 10,300 shares, the short-interest ratio is currently 29.8 days. Approximately 6.4% of the company’s shares are short sold.

Lumos Pharma Stock Up 4.9 %

NASDAQ:LUMO opened at $8.18 on Friday. The company has a fifty day moving average of $7.52 and a 200 day moving average of $8.40. Lumos Pharma has a 52 week low of $6.15 and a 52 week high of $11.52. The firm has a market capitalization of $68.46 million, a P/E ratio of -2.31 and a beta of 1.24.

Lumos Pharma (NASDAQ:LUMOGet Rating) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($0.92) EPS for the quarter, meeting analysts’ consensus estimates of ($0.92). The firm had revenue of $0.11 million for the quarter. As a group, analysts anticipate that Lumos Pharma will post -3.93 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Oppenheimer started coverage on shares of Lumos Pharma in a report on Tuesday, July 19th. They set an “outperform” rating and a $20.00 price target for the company.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Urban Wealth Management LLC bought a new position in Lumos Pharma in the 2nd quarter worth $27,000. PVG Asset Management Corp bought a new position in Lumos Pharma in the 4th quarter worth $71,000. Envestnet Asset Management Inc. bought a new position in Lumos Pharma in the 4th quarter worth $72,000. Key Financial Inc bought a new position in Lumos Pharma in the 2nd quarter worth $84,000. Finally, Private Advisor Group LLC bought a new position in Lumos Pharma in the 1st quarter worth $263,000. 38.35% of the stock is currently owned by institutional investors.

Lumos Pharma Company Profile

(Get Rating)

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders.

Featured Stories

Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.